Nektar Therapeutics (NKTR) Receivables - Other (2018 - 2025)

Nektar Therapeutics' Receivables - Other history runs 8 years deep, the most recent figure standing at $600000.0 for Q4 2025.

• On a quarterly basis, Receivables - Other fell 45.45% year-over-year to $600000.0 in Q4 2025; TTM through Dec 2025 was $600000.0, a 45.45% decrease from a year earlier, with the FY2025 full-year figure at $600000.0, down 45.45% from the prior year.
• Receivables - Other slipped to $600000.0 in Q4 2025 per NKTR's latest filing, from $1.1 million in the prior quarter.
• Across five years, Receivables - Other topped out at $1.4 million in Q4 2021 and bottomed at $500000.0 in Q4 2023.
• The 5-year median for Receivables - Other is $700000.0 (2022), against an average of $860000.0.
• Across the five-year window, Receivables - Other tumbled 72.55% in 2021 and surged 120.0% in 2024, its largest moves.
• Year by year, Receivables - Other stood at $1.4 million in 2021, then sank by 50.0% to $700000.0 in 2022, then decreased by 28.57% to $500000.0 in 2023, then surged by 120.0% to $1.1 million in 2024, then plunged by 45.45% to $600000.0 in 2025.
• Per Business Quant, the three latest NKTR Receivables - Other figures stand at $600000.0 (Q4 2025), $1.1 million (Q4 2024), and $500000.0 (Q4 2023).